Key enablers and barriers to implementing adaptive pathways in the European setting
Open Access
- 8 March 2019
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (7) , 1427-1433
Abstract
In 2016, the European Medicines Agency published the conclusions of its pilot on adaptive pathways, with products in early stages of development still building up to their marketing authorisation. Adaptive pathways rests on three principles: iterative development; gathering evidence through real‐life use to supplement clinical trial data; and early engagement of patients, payers and health technology assessment bodies in discussions on a medicine's development. While the pilot has now finished, the practical system‐wide implications of employing the adaptive pathways approach are not known and further consideration of these three principles is required. In this paper we used the three principles that underpin adaptive pathways to discuss main scientific and European policy developments likely to determine progress on further implementing adaptive pathways in the European setting.Keywords
Funding Information
- Innovative Medicines Initiative 2 Joint Undertaking (115890)
This publication has 17 references indexed in Scilit:
- The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and ImplicationsPharmacoEconomics, 2017
- Evidence for Health Decision Making — Beyond Randomized, Controlled TrialsNew England Journal of Medicine, 2017
- Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the FutureFrontiers in Pharmacology, 2017
- Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA AgenciesValue in Health, 2017
- Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewJournal of Personalized Medicine, 2017
- Health Technology Assessment in the Context of Adaptive Pathways for Medicines in Europe: Challenges and OpportunitiesClinical Pharmacology & Therapeutics, 2016
- Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysFrontiers in Pharmacology, 2016
- Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewPLOS ONE, 2016
- MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITYInternational Journal of Technology Assessment in Health Care, 2015
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013